Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
portefeuille
(99.81)
Submitted: 12/15/2011 9:33:52 PM :
Start Price:
$11.76
ARIA Score:
+21.74
There are currently 400 ARIA shares in my "fund" with break-even of around -47.31 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
KurtEng
(51.17)
Submitted: 8/17/2011 4:27:00 PM :
Start Price:
$9.13
ARIA Score:
-45.18
It could be a winner, but it is a LONG shot. I would rather bet on 6 red.
Recs
Allstar13913
(99.84)
Submitted: 7/30/2011 8:01:17 PM :
Start Price:
$9.21
ARIA Score:
-41.63
Another overvalued Biotech company. This company has never been profitable and seems to make all its money off partnerships.
http://www.fool.com/investing/general/2011/06/10/3-stocks-near-52-week-highs-worth-selling.aspx
Recs
polterziets
(41.13)
Submitted: 6/4/2011 5:51:01 PM :
Start Price:
$7.90
ARIA Score:
+82.06
growth and very undervalued
Recs
phatchips767
(< 20)
Submitted: 5/21/2011 2:06:32 PM :
Start Price:
$8.59
ARIA Score:
+68.80
pe of 14. One of the big monkees i watch likes it.
Recs
edizzo1
(< 20)
Submitted: 5/16/2011 12:17:14 AM :
Start Price:
$9.13
ARIA Score:
+59.92
Right now ARIA has everything going for it to see some big profits. I think it is a buy and I think we will see $20.00 a shear this year.
Ed Izzo
Recs
jcam180
(28.66)
Submitted: 5/12/2011 8:29:02 PM :
Start Price:
$9.24
ARIA Score:
+59.19
little money big upside, good products in pipeline
Recs
RazorSphinx
(< 20)
Submitted: 4/28/2011 7:31:45 AM :
Start Price:
$8.30
ARIA Score:
+77.36
Magic Formula
Recs
calor
(< 20)
Submitted: 4/6/2011 1:17:57 AM :
Start Price:
$8.48
ARIA Score:
+72.46
I have followed ARIA during 8 years, the research and technology in progress is very sophisticated, it will treat tumors that currently have no therapies and very poor prognosis. It will eventually take over by MERCK(MRK) which currently has a deal in one of the leading drugs to co-promote. Annual projected income in just this product is upwards of 1 Billion, profits to be shared. More to come from this great biotech company
Recs
syazic
(72.86)
Submitted: 3/28/2011 4:56:52 PM :
Start Price:
$7.27
ARIA Score:
+98.91
UPWARD trend is set.
Recs
joshcollis
(< 20)
Submitted: 3/8/2011 5:21:46 PM :
Start Price:
$6.01
ARIA Score:
+142.30
Solid management team and interesting products
Recs
reachmygoals1
(< 20)
Submitted: 2/1/2011 1:07:15 AM :
Start Price:
$6.42
ARIA Score:
+124.49
phase 3 sarcoma was successful. eun yang of jefferies and company have current price target at $11.00 next year will be huge.
Recs
OnTheClock
(< 20)
Submitted: 1/13/2011 2:36:41 PM :
Start Price:
$5.15
ARIA Score:
+179.84
With Merck and Ariad both touting Q1 for rida Phase II results and the push for FDA approval, I'd expect things to gain some steam moving into late February. Most have given a likelihood of FDA approval around 60%.
Recs
zzlangerhans
(99.26)
Submitted: 12/2/2010 12:36:55 AM :
Start Price:
$4.08
ARIA Score:
-246.21
Ariad's share price has bounced around a lot this year in advance of data from the phase III SUCCEED trial of ridaforolimus in metastatic sarcoma, and is now close to a three year high (and a six-year high in market cap). A 540M cap is simply too much given the questionable odds of success of ridaforolimus against a tough solid tumor like sarcoma, and a cash position of only 60M.
For those interested in put options, the ask on the May 4's is 1.10 today and I would expect a SUCCEED failure to send the share price below 1. That would represent a $190 profit per contract. The open interest on the May 2.50 puts is really high. I'll keep following the prices on these and consider a hit if the put prices continue to drop.
Recs
muffmutt
(58.76)
Submitted: 11/30/2010 3:33:55 AM :
Start Price:
$3.91
ARIA Score:
+260.92
echnicals
Recs
HunNemo
(65.04)
Submitted: 6/7/2010 4:46:43 PM :
Start Price:
$3.31
ARIA Score:
+315.48
Cramer pharma
Recs
otterfolly
(< 20)
Submitted: 5/26/2010 5:06:04 PM :
Start Price:
$3.66
ARIA Score:
+277.36
Cambridge brains.
Recs
crapsshooter
(97.99)
Submitted: 4/21/2010 1:43:04 PM :
Start Price:
$3.71
ARIA Score:
+283.70
good presntation. good results. good prospects only upside do i see
Recs
JesusForgives
(71.58)
Submitted: 4/1/2010 5:31:14 AM :
Start Price:
$3.41
ARIA Score:
+315.71
This stock could just be a good pick to do a cover call option for may10 if my figures are right you could see a return of 14% for the month.
Recs
Hetuck
(< 20)
Submitted: 3/19/2010 9:23:03 AM :
Start Price:
$3.19
ARIA Score:
+344.53
Based on my analysis this stock still has room to grow. I'm looking at for at least a 50% increase, if not a little more, from now to year's end to $4.75 - if all stays on course. This is a speculative stock with good chances for appreciation. If you can hold for 6 months to a year you should do well - if the economy stays on course.
As with all recommendations please make sure it fits your own personal profile before investing.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 49 : 1 2 3 Next »